<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T10:12:13Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:6532882" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:6532882</identifier>
        <datestamp>2019-06-05</datestamp>
        <setSpec>plosone</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">PLoS One</journal-id>
              <journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id>
              <journal-id journal-id-type="publisher-id">plos</journal-id>
              <journal-id journal-id-type="pmc">plosone</journal-id>
              <journal-title-group>
                <journal-title>PLoS ONE</journal-title>
              </journal-title-group>
              <issn pub-type="epub">1932-6203</issn>
              <publisher>
                <publisher-name>Public Library of Science</publisher-name>
                <publisher-loc>San Francisco, CA USA</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC6532882</article-id>
              <article-id pub-id-type="pmcid">PMC6532882</article-id>
              <article-id pub-id-type="pmc-uid">6532882</article-id>
              <article-id pub-id-type="pmid">31120957</article-id>
              <article-id pub-id-type="doi">10.1371/journal.pone.0217091</article-id>
              <article-id pub-id-type="publisher-id">PONE-D-18-36733</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Research Article</subject>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Cell Biology</subject>
                    <subj-group>
                      <subject>Cellular Types</subject>
                      <subj-group>
                        <subject>Animal Cells</subject>
                        <subj-group>
                          <subject>Blood Cells</subject>
                          <subj-group>
                            <subject>White Blood Cells</subject>
                            <subj-group>
                              <subject>T Cells</subject>
                            </subj-group>
                          </subj-group>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Cell Biology</subject>
                    <subj-group>
                      <subject>Cellular Types</subject>
                      <subj-group>
                        <subject>Animal Cells</subject>
                        <subj-group>
                          <subject>Immune Cells</subject>
                          <subj-group>
                            <subject>White Blood Cells</subject>
                            <subj-group>
                              <subject>T Cells</subject>
                            </subj-group>
                          </subj-group>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Immunology</subject>
                    <subj-group>
                      <subject>Immune Cells</subject>
                      <subj-group>
                        <subject>White Blood Cells</subject>
                        <subj-group>
                          <subject>T Cells</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Immunology</subject>
                    <subj-group>
                      <subject>Immune Cells</subject>
                      <subj-group>
                        <subject>White Blood Cells</subject>
                        <subj-group>
                          <subject>T Cells</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Physiology</subject>
                    <subj-group>
                      <subject>Immune Physiology</subject>
                      <subj-group>
                        <subject>Cytokines</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Physiology</subject>
                    <subj-group>
                      <subject>Immune Physiology</subject>
                      <subj-group>
                        <subject>Cytokines</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Immunology</subject>
                    <subj-group>
                      <subject>Immune System</subject>
                      <subj-group>
                        <subject>Innate Immune System</subject>
                        <subj-group>
                          <subject>Cytokines</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Immunology</subject>
                    <subj-group>
                      <subject>Immune System</subject>
                      <subj-group>
                        <subject>Innate Immune System</subject>
                        <subj-group>
                          <subject>Cytokines</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Developmental Biology</subject>
                    <subj-group>
                      <subject>Molecular Development</subject>
                      <subj-group>
                        <subject>Cytokines</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Infectious Diseases</subject>
                    <subj-group>
                      <subject>Infectious Disease Control</subject>
                      <subj-group>
                        <subject>Vaccines</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Infectious Diseases</subject>
                    <subj-group>
                      <subject>Bacterial Diseases</subject>
                      <subj-group>
                        <subject>Tuberculosis</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Tropical Diseases</subject>
                    <subj-group>
                      <subject>Tuberculosis</subject>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Organisms</subject>
                    <subj-group>
                      <subject>Bacteria</subject>
                      <subj-group>
                        <subject>Actinobacteria</subject>
                        <subj-group>
                          <subject>Mycobacterium Tuberculosis</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Infectious Diseases</subject>
                    <subj-group>
                      <subject>Infectious Disease Control</subject>
                      <subj-group>
                        <subject>Vaccines</subject>
                        <subj-group>
                          <subject>Booster Doses</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Immunology</subject>
                    <subj-group>
                      <subject>Immune Response</subject>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Immunology</subject>
                    <subj-group>
                      <subject>Immune Response</subject>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Infectious Diseases</subject>
                    <subj-group>
                      <subject>Zoonoses</subject>
                      <subj-group>
                        <subject>Bovine Tuberculosis</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>CD4+ T cell cytokine responses to the DAR-901 booster vaccine in BCG-primed adults: A randomized, placebo-controlled trial</article-title>
                <alt-title alt-title-type="running-head">CD4+ T cell cytokine responses to the DAR-901 booster vaccine in BCG-primed adults</alt-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-3663-8965</contrib-id>
                  <name>
                    <surname>Masonou</surname>
                    <given-names>Tereza</given-names>
                  </name>
                  <role content-type="http://credit.casrai.org/">Conceptualization</role>
                  <role content-type="http://credit.casrai.org/">Formal analysis</role>
                  <role content-type="http://credit.casrai.org/">Writing – original draft</role>
                  <role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff001">
                    <sup>1</sup>
                  </xref>
                  <xref ref-type="author-notes" rid="currentaff001">
                    <sup>¤a</sup>
                  </xref>
                  <xref ref-type="corresp" rid="cor001">*</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-6184-2485</contrib-id>
                  <name>
                    <surname>Hokey</surname>
                    <given-names>David A.</given-names>
                  </name>
                  <role content-type="http://credit.casrai.org/">Investigation</role>
                  <role content-type="http://credit.casrai.org/">Methodology</role>
                  <role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff002">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-1081-9269</contrib-id>
                  <name>
                    <surname>Lahey</surname>
                    <given-names>Timothy</given-names>
                  </name>
                  <role content-type="http://credit.casrai.org/">Conceptualization</role>
                  <role content-type="http://credit.casrai.org/">Data curation</role>
                  <role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff003">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Halliday</surname>
                    <given-names>Alice</given-names>
                  </name>
                  <role content-type="http://credit.casrai.org/">Formal analysis</role>
                  <role content-type="http://credit.casrai.org/">Methodology</role>
                  <role content-type="http://credit.casrai.org/">Supervision</role>
                  <role content-type="http://credit.casrai.org/">Visualization</role>
                  <role content-type="http://credit.casrai.org/">Writing – original draft</role>
                  <role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff001">
                    <sup>1</sup>
                  </xref>
                  <xref ref-type="author-notes" rid="currentaff002">
                    <sup>¤b</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-1634-9971</contrib-id>
                  <name>
                    <surname>Berrocal-Almanza</surname>
                    <given-names>Luis C.</given-names>
                  </name>
                  <role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Wieland-Alter</surname>
                    <given-names>Wendy F.</given-names>
                  </name>
                  <role content-type="http://credit.casrai.org/">Investigation</role>
                  <xref ref-type="aff" rid="aff004">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Arbeit</surname>
                    <given-names>Robert D.</given-names>
                  </name>
                  <role content-type="http://credit.casrai.org/">Resources</role>
                  <role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff005">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Lalvani</surname>
                    <given-names>Ajit</given-names>
                  </name>
                  <role content-type="http://credit.casrai.org/">Supervision</role>
                  <role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff001">
                    <sup>1</sup>
                  </xref>
                  <xref ref-type="corresp" rid="cor001">*</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>von Reyn</surname>
                    <given-names>C. Fordham</given-names>
                  </name>
                  <role content-type="http://credit.casrai.org/">Conceptualization</role>
                  <role content-type="http://credit.casrai.org/">Data curation</role>
                  <role content-type="http://credit.casrai.org/">Funding acquisition</role>
                  <role content-type="http://credit.casrai.org/">Investigation</role>
                  <role content-type="http://credit.casrai.org/">Methodology</role>
                  <role content-type="http://credit.casrai.org/">Project administration</role>
                  <role content-type="http://credit.casrai.org/">Resources</role>
                  <role content-type="http://credit.casrai.org/">Supervision</role>
                  <role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff004">
                    <sup>4</sup>
                  </xref>
                  <xref ref-type="author-notes" rid="currentaff003">
                    <sup>¤c</sup>
                  </xref>
                  <xref ref-type="corresp" rid="cor001">*</xref>
                </contrib>
              </contrib-group>
              <aff id="aff001">
                <label>1</label>
                <addr-line>Tuberculosis Research Centre, Respiratory Infections Section, National Heart and Lung Institute, Imperial College London, London, United Kingdom</addr-line>
              </aff>
              <aff id="aff002">
                <label>2</label>
                <addr-line>Aeras, Rockville, MD, United States of America</addr-line>
              </aff>
              <aff id="aff003">
                <label>3</label>
                <addr-line>Larner College of Medicine, University of Vermont, Burlington, VT, United States of America</addr-line>
              </aff>
              <aff id="aff004">
                <label>4</label>
                <addr-line>Geisel School of Medicine, Hanover, NH, United States of America</addr-line>
              </aff>
              <aff id="aff005">
                <label>5</label>
                <addr-line>Tufts University School of Medicine, Boston, MA, United States of America</addr-line>
              </aff>
              <contrib-group>
                <contrib contrib-type="editor">
                  <name>
                    <surname>Izzo</surname>
                    <given-names>Angelo A.</given-names>
                  </name>
                  <role>Editor</role>
                  <xref ref-type="aff" rid="edit1"/>
                </contrib>
              </contrib-group>
              <aff id="edit1">
                <addr-line>Colorado State University, UNITED STATES</addr-line>
              </aff>
              <author-notes>
                <fn fn-type="COI-statement" id="coi001">
                  <p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p>
                </fn>
                <fn fn-type="current-aff" id="currentaff001">
                  <label>¤a</label>
                  <p>Current address: MRC Centre of Molecular Bacteriology and Infection, Imperial College London, London, United Kingdom</p>
                </fn>
                <fn fn-type="current-aff" id="currentaff002">
                  <label>¤b</label>
                  <p>Current address: Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom</p>
                </fn>
                <fn fn-type="current-aff" id="currentaff003">
                  <label>¤c</label>
                  <p>Current address: Infectious Disease and International Health, Geisel School of Medicine, DHMC, Lebanon, NH, United States of America</p>
                </fn>
                <corresp id="cor001">* E-mail: <email>tereza.masonou16@imperial.ac.uk</email> (TM);<email>a.lalvani@imperial.ac.uk</email> (AL); <email>fvr@dartmouth.edu</email> (CFvR)</corresp>
              </author-notes>
              <pub-date pub-type="epub">
                <day>23</day>
                <month>5</month>
                <year>2019</year>
              </pub-date>
              <pub-date pub-type="collection">
                <year>2019</year>
              </pub-date>
              <volume>14</volume>
              <issue>5</issue>
              <elocation-id>e0217091</elocation-id>
              <history>
                <date date-type="received">
                  <day>22</day>
                  <month>12</month>
                  <year>2018</year>
                </date>
                <date date-type="accepted">
                  <day>30</day>
                  <month>4</month>
                  <year>2019</year>
                </date>
              </history>
              <permissions>
                <license xlink:href="https://creativecommons.org/publicdomain/zero/1.0/">
                  <license-p>This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/publicdomain/zero/1.0/">Creative Commons CC0</ext-link> public domain dedication.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:href="pone.0217091.pdf"/>
              <abstract>
                <sec id="sec001">
                  <title>Background</title>
                  <p>DAR-901 is an inactivated whole cell tuberculosis booster vaccine, prepared using a new scalable, broth-grown method from the master cell bank of SRL172, a vaccine previously shown to prevent tuberculosis. This study examined whether DAR-901 (a) induces CD4+ T cell cytokine profiles previously proposed as correlates of protection and (b) has a specific vaccine-induced immunological signature compared to BCG or placebo.</p>
                </sec>
                <sec id="sec002">
                  <title>Methods</title>
                  <p>We analysed CD4+ T cell cytokine immune responses from 10 DAR-901 recipients, 9 BCG recipients and 9 placebo recipients from the Phase I DAR-901 MDES trial. In that study, HIV-negative, IGRA-negative participants with prior BCG immunization were randomized (double-blind) to receive three intradermal injections of DAR-901 or saline placebo or two injections of saline placebo followed by an intradermal injection of BCG. Antigen-specific functional and phenotypic CD4+ T cell responses along with effector phenotype of responder cells were measured by intracellular cytokine staining.</p>
                </sec>
                <sec id="sec003">
                  <title>Results</title>
                  <p>DAR-901 recipients exhibited increased DAR-901 antigen-specific polyfunctional or bifunctional T cell responses compared to baseline. Vaccine specific CD4+ IFNγ, IL2, TNFα and any cytokine responses peaked at 7 days post-dose 3. Th1 responses predominated, with most responder cells exhibiting a polyfunctional effector memory phenotype. BCG induced greater CD4+ T cell responses than placebo while the more modest DAR-901 responses did not differ from placebo. Neither DAR-901 nor BCG induced substantial or sustained Th17 /Th22 cytokine responses.</p>
                </sec>
                <sec id="sec004">
                  <title>Conclusion</title>
                  <p>DAR-901, a TB booster vaccine grown from the master cell bank of SRL 172 which was shown to prevent TB, induced low magnitude polyfunctional effector memory CD4+ T cell responses. DAR-901 responses were lower than those induced by BCG, a vaccine that has been shown ineffective as a booster to prevent tuberculosis disease. These results suggest that induction of higher levels of CD4+ cytokine stimulation may not be a critical or pre-requisite characteristic for candidate TB vaccine boosters.</p>
                </sec>
                <sec id="sec005">
                  <title>Trial registration</title>
                  <p>ClinicalTrials.gov <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02063555">NCT02063555</ext-link>.</p>
                </sec>
              </abstract>
              <funding-group>
                <funding-statement>Support was provided by: (1) Dartmouth College - university grant (no number), (2) Aeras Foundation - supporting grant (no number), (3) Jack and Dorothy Byrne Foundation (no number), (4) Imperial College London. AL received funding award from the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Respiratory Infections at Imperial College London in partnership with Public Health England (PHE) – grant code 10064, which supported salaries for the following: AL, TM, LBA. In addition, AL received funding via the Imperial NIHR BRC (Biomedical Research Centre) – grant code 1215-20013 which supported salaries for AH and AL (<ext-link ext-link-type="uri" xlink:href="https://www.nihr.ac.uk/">https://www.nihr.ac.uk/</ext-link>). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement>
              </funding-group>
              <counts>
                <fig-count count="5"/>
                <table-count count="0"/>
                <page-count count="17"/>
              </counts>
              <custom-meta-group>
                <custom-meta id="data-availability">
                  <meta-name>Data Availability</meta-name>
                  <meta-value>All relevant data are within the manuscript and its Supporting Information files.</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
            <notes>
              <title>Data Availability</title>
              <p>All relevant data are within the manuscript and its Supporting Information files.</p>
            </notes>
          </front>
          <body>
            <sec sec-type="intro" id="sec006">
              <title>Introduction</title>
              <p>Tuberculosis (TB) is the leading infectious cause of death in the world and has been targeted for eradication by 2030 [<xref rid="pone.0217091.ref001" ref-type="bibr">1</xref>]. An improved vaccine strategy against TB will be essential for the success of this effort. The only currently licensed vaccine for TB prevention is <italic>Mycobacterium bovis</italic> bacillus Calmette-Guérin (BCG). Although newer analyses indicate that BCG is highly effective against pulmonary tuberculosis when given at birth, local side effects are common, and efficacy decreases after 15–20 years [<xref rid="pone.0217091.ref002" ref-type="bibr">2</xref>]. Thus, TB vaccine development includes both new priming vaccines to replace BCG and vaccines to boost BCG. Development has been challenging since a new vaccine must be safe in HIV and be effective in both persons with and without latent TB [<xref rid="pone.0217091.ref003" ref-type="bibr">3</xref>]. Modelling studies indicate that a booster vaccine with a 10-year protective duration and 40% efficacy targeted at adolescents/adults will have a greater impact on TB epidemiology than an improved BCG prime [<xref rid="pone.0217091.ref004" ref-type="bibr">4</xref>].</p>
              <p>TB vaccine development has been hampered by the lack of a vaccine-induced correlate of protection. Identification of such a correlate will necessarily involve assaying immune responses from subjects in a clinical trial in which efficacy was demonstrated. The correlate may differ for priming versus boosting vaccines and for vaccines that prevent TB infection versus vaccines that prevent TB disease [<xref rid="pone.0217091.ref005" ref-type="bibr">5</xref>,<xref rid="pone.0217091.ref006" ref-type="bibr">6</xref>]. BCG priming has been shown to prevent both TB disease and TB infection [<xref rid="pone.0217091.ref007" ref-type="bibr">7</xref>,<xref rid="pone.0217091.ref008" ref-type="bibr">8</xref>], but clinical samples are not available from these older studies. BCG boosting has been shown ineffective in the prevention of TB disease [<xref rid="pone.0217091.ref009" ref-type="bibr">9</xref>,<xref rid="pone.0217091.ref010" ref-type="bibr">10</xref>] but was recently shown to reduce the risk of TB infection in adolescents in South Africa and results from immune assays on these subjects are pending [<xref rid="pone.0217091.ref011" ref-type="bibr">11</xref>,<xref rid="pone.0217091.ref012" ref-type="bibr">12</xref>].</p>
              <p>Two modern TB vaccine candidates have demonstrated efficacy against microbiologically-confirmed TB disease: agar-grown SRL172 inactivated whole cell booster vaccine [<xref rid="pone.0217091.ref013" ref-type="bibr">13</xref>] and the M72/AS01<sub>E</sub> vaccine [<xref rid="pone.0217091.ref014" ref-type="bibr">14</xref>]. Both SRL172 and M72/AS01<sub>E</sub> elicit humoral and cellular immune responses in humans [<xref rid="pone.0217091.ref006" ref-type="bibr">6</xref>,<xref rid="pone.0217091.ref015" ref-type="bibr">15</xref>]. Immune assays from the SRL172 trial did not identify a correlate of protection, and immune assays are pending on the M72/AS01<sub>E</sub> trial. DAR-901 is prepared from the Master Cell Bank of agar-grown SRL172 by a new scalable, broth-grown manufacturing method. Murine studies demonstrated that, compared to a BCG booster the DAR-901 booster conferred superior protection from TB challenge [<xref rid="pone.0217091.ref016" ref-type="bibr">16</xref>]. A Phase 1 trial of the DAR-901 booster showed safety and immunogenicity [<xref rid="pone.0217091.ref017" ref-type="bibr">17</xref>] and a Phase 2b Prevention of Infection Trial is underway in Tanzania.</p>
              <p>Proposed correlates of vaccine-induced protection consist almost entirely of one or another form of <italic>Mycobacterium tuberculosis</italic> (Mtb)-specific Th1 cells, producing either IFNγ, TNFα or IL2. These cells are considered an important component of anti-Mtb immunity, and are believe to function by recruiting and activating innate immune cells and restricting Mtb bacterial expansion [<xref rid="pone.0217091.ref018" ref-type="bibr">18</xref>]. Although these cytokines are induced by BCG [<xref rid="pone.0217091.ref019" ref-type="bibr">19</xref>–<xref rid="pone.0217091.ref022" ref-type="bibr">22</xref>], recent studies evaluating IFNγ producing T cells failed to identify this subset either as protective against Mtb or as a useful predictor of vaccine effectiveness [<xref rid="pone.0217091.ref023" ref-type="bibr">23</xref>–<xref rid="pone.0217091.ref025" ref-type="bibr">25</xref>], although this cell subset was correlated with Mtb bacterial load [<xref rid="pone.0217091.ref025" ref-type="bibr">25</xref>].</p>
              <p>Polyfunctional CD4+ T cells producing IFNγ, TNFα and IL2 and bifunctional T cells expressing dual combinations of these cytokines have also been proposed as vaccine-induced correlates of protection [<xref rid="pone.0217091.ref020" ref-type="bibr">20</xref>,<xref rid="pone.0217091.ref021" ref-type="bibr">21</xref>,<xref rid="pone.0217091.ref026" ref-type="bibr">26</xref>–<xref rid="pone.0217091.ref031" ref-type="bibr">31</xref>], but there are mixed observations regarding this hypothesis. For example, while an observational study comparing BCG vaccinated versus non-vaccinated calves revealed an increased polyfunctional response correlated with protection [<xref rid="pone.0217091.ref032" ref-type="bibr">32</xref>], this correlation was not seen in an investigational study of rhesus macaques [<xref rid="pone.0217091.ref033" ref-type="bibr">33</xref>,<xref rid="pone.0217091.ref034" ref-type="bibr">34</xref>]. Additional studies in both vaccinated and unvaccinated cynomolgus macaques, have shown control of a TB challenge correlated with Th17/Th22 associated cytokines, IL17 and IL22 [<xref rid="pone.0217091.ref019" ref-type="bibr">19</xref>,<xref rid="pone.0217091.ref035" ref-type="bibr">35</xref>–<xref rid="pone.0217091.ref042" ref-type="bibr">42</xref>].</p>
              <p>Among human trials, the H4:IC31 subunit booster vaccine induced high frequencies of CD4 T cells composed of polyfunctional or bifunctional (IL2+TNFα+) cells [<xref rid="pone.0217091.ref030" ref-type="bibr">30</xref>]. However, in BCG-vaccinated South African infants there was no correlation between the number of BCG-elicited polyfunctional T cells and prevention of disease [<xref rid="pone.0217091.ref023" ref-type="bibr">23</xref>]. In a Phase 2 trial the MVA85A subunit vaccine booster failed to confer protection against TB in healthy BCG vaccinated infants [<xref rid="pone.0217091.ref043" ref-type="bibr">43</xref>] despite providing heightened and durable Th1 and polyfunctional T cells responses [<xref rid="pone.0217091.ref044" ref-type="bibr">44</xref>,<xref rid="pone.0217091.ref045" ref-type="bibr">45</xref>]. There is limited clinical data addressing the role of Th17/Th22 responses.</p>
              <p>In the present study we assayed proposed cytokine correlates of immune protection in BCG-primed subjects from the Phase 1 trial of DAR-901. We sought to determine whether previously identified correlates of protection were induced and how these responses compared to those induced by a BCG booster.</p>
            </sec>
            <sec sec-type="materials|methods" id="sec007">
              <title>Materials and methods</title>
              <sec id="sec008">
                <title>Trial design, setting and population</title>
                <p>The DAR-901 MDES trial was a 59-subject randomized, placebo-controlled, double-blind, Phase 1 trial of a booster strategy for the prevention of tuberculosis in adult subjects aged 18–65 with a history of prior BCG immunization. Subjects included healthy IGRA negative and IGRA positive adults with and without HIV infection. The trial design has been previously described <xref ref-type="supplementary-material" rid="pone.0217091.s003">S1 Fig</xref> [<xref rid="pone.0217091.ref017" ref-type="bibr">17</xref>]. The present study focused on a subset of IGRA-negative subjects in the randomized dose escalation groups (cohorts A1-A3) and included a total of 28 subjects: the 10 recipients of the three 1.0 mg intradermal doses of DAR-901 (A3 cohort, the dose that has been selected for further clinical trials), the pool of 9 subjects (3 each in dose escalation cohorts A1–A3) who received 3 intradermal doses of saline placebo, and the pool of 9 subjects who received two dose of saline followed by a single intradermal dose of BCG (<xref ref-type="fig" rid="pone.0217091.g001">Fig 1</xref>). DAR-901 was produced by Aeras (Rockville, MD, USA) in compliance with Good Manufacturing Practices (7 x 10<sup>6</sup> CFU / for 1 mg). Saline placebo was obtained as Sterile Saline for Injection USP, and BCG was obtained as TICE BCG (1–8 x 10<sup>6</sup> CFU) (Organon Teknika, Durham, North Carolina, USA [<xref rid="pone.0217091.ref017" ref-type="bibr">17</xref>]. Intradermal injections of 0.1 mL were given at 0,2,4 months over the deltoid muscle alternating between right and left arms. Of note, the ten IGRA-negative subjects who received 1.0mg DAR-901 in the A3 cohort remained IGRA negative by the end of the study [<xref rid="pone.0217091.ref017" ref-type="bibr">17</xref>].</p>
                <fig id="pone.0217091.g001" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0217091.g001</object-id>
                  <label>Fig 1</label>
                  <caption>
                    <title>Schematic vaccination timeline of the total vaccinated subjects (n = 28) included in this study.</title>
                    <p>Subjects within each group were randomized 1:1:3 to receive three doses of saline placebo-group 1 or two of saline followed by BCG (1–8 x 10<sup>6</sup> CFU)-group 2, or three injections of DAR-901 7 x 10<sup>6</sup> CFU / for 1 mg)-group 3. Blood samples for CD4+ T cell cytokine expression analyses were collected at baseline/pre-dose 1, pre-dose 2 and pre-dose 3 (responses measured prior to administration of respective treatment) and at 7,28,56 and 180-days after dose 3.</p>
                  </caption>
                  <graphic xlink:href="pone.0217091.g001"/>
                </fig>
              </sec>
              <sec id="sec009">
                <title>Participants safety and enrolment</title>
                <p>The DAR-901 MDES study protocol and details of the design, implementation, and safety experience in the Phase 1 DAR-901 MDES trial have been reported previously [<xref rid="pone.0217091.ref017" ref-type="bibr">17</xref>].</p>
              </sec>
              <sec id="sec010">
                <title>Ethical approval</title>
                <p>Ethical approval was obtained from the Committee for the Protection of Human subjects with ethics number #24499 at Dartmouth-Hitchcock Medical Center on 29<sup>th</sup> January 2014. We obtained written informed consent from all subjects.</p>
              </sec>
              <sec id="sec011">
                <title>Immunology assays</title>
                <p>We collected blood for immune assays from the subjects within each group at baseline (pre-dose1), pre-dose 2, pre-dose 3 and at 7, 28, 56 and 180 days after dose 3. Vaccine-specific CD4+ T cell responses were measured from blood samples by flow cytometric intracellular staining (ICS) as described previously [<xref rid="pone.0217091.ref046" ref-type="bibr">46</xref>]. Thawed PBMCs resuspended in R10 medium, were rested overnight in 37°C, 5% CO<sub>2</sub> incubator. Following the overnight rest, cells were counted using Guava easyCyte Flow Cytometer, cells were plated at a final concentration of 1 x 10<sup>6</sup> cells per well and stimulated with medium/R10 as a negative control, staphylococcal enterotoxin B (SEB; 0.5 μg/mL) as the positive control, DAR-901 lysate or Mtb whole cell lysate at a concentration of 5 μg/mL and BCG (3 x10<sup>5</sup> CFU/well). To aid in antigen processing and presentation, anti-CD28 and anti-CD49d antibodies (1 uL each per well; both from BD) were added to each well. Cells were incubated in a humidified 37 <sup>o</sup>C, 5% CO<sub>2</sub> incubator for 2 hrs before the addition of GolgiPlug, GolgiStop and anti-CD107a followed by an additional incubation for 6–7 hrs at 37 <sup>o</sup>C and 5% CO<sub>2</sub>, after which the cells were placed at 2–8°C overnight. Cells were stained with Live/Dead viability dye, followed by fluorochrome-conjugated antibodies to surface markers CD4-APC, CD45RO-BV785, CCR7-BV605 then fixed and permeabilized for intracellular staining with CD3-ECD, CD8-AlexaFluor700 IFNγ-V450, TNFα-PE-Cy7, IL2-PE, IL22-APC, IL17A-PerCP-Cy5.5 and CD154-PE-Cy5. CD154 was included in the panel as a specific and sensitive marker in detecting CD4 responses [<xref rid="pone.0217091.ref047" ref-type="bibr">47</xref>]. Following incubation cells were washed, fixed and analysed by BD LSR flow cytometer. Analyses of flow cytometry data were performed using FlowJo v.10 using the gating template as described previously [<xref rid="pone.0217091.ref046" ref-type="bibr">46</xref>]. Stopping gates were set to 150,000 CD3 T cells and sufficient events (no less than 5000 CD4/CD8 T cells) were collected for analysis. Data reported are restricted to CD4+ responses as screening analyses revealed no vaccine-specific CD8+ responses using this assay.</p>
              </sec>
              <sec id="sec012">
                <title>Statistical analysis</title>
                <p>Data analyses were performed using GraphPad Prism v7. For immune assays, median responses pre and post challenge were compared using a Wilcoxon signed-rank test (within groups). To compare between groups our analysis included calculating the area under the curve (AUC) for responses in post-dosing time points, for immune read-outs. For non-Gaussian data, non-parametric tests were used to compared AUC values between groups using Mann Whitney U test or Kruskal-Wallis to assess differences between three groups. The threshold for the level of significance was set at a P value of &lt;0.05.</p>
              </sec>
            </sec>
            <sec sec-type="results" id="sec013">
              <title>Results</title>
              <sec id="sec014">
                <title>DAR-901 vaccine responses at 7-days post dose 3 increased compared to baseline</title>
                <p>DAR-901 recipients demonstrated measurable increases in CD4+ T cell cytokine responses compared to baseline. DAR-901 vaccine specific CD4+ IFNγ, IL2, TNFα and any cytokine responses peaked at 7-days post-dose 3 and were significantly greater than the pre-dosing time point (see <xref ref-type="supplementary-material" rid="pone.0217091.s001">S1 Table</xref> for inter-group comparisons at each timepoint). By 180-days post-dose 3, the total CD4+ T cell cytokine production was significantly reduced from their peak levels measured at 7-days post-dose 3. However, at no time point were the responses significantly higher than the placebo group (<xref ref-type="supplementary-material" rid="pone.0217091.s004">S2 Fig</xref>). The frequency of antigen specific CD4+ T cell expression of total IL17 and total IL22 were negligible in all groups and for all stimuli.</p>
                <p>We evaluated whether DAR-901 vaccine resulted in the induction of Mtb-specific CD4+ T cell cytokine producing T cells with Th1 or Th17/Th22 cytokines. There were no evident differences in the frequency of Mtb-specific CD4+ T cells producing IFNγ, TNFα, IL2, IL17 and IL22 at baseline compared with post-dose time points (<xref ref-type="supplementary-material" rid="pone.0217091.s001">S1 Table</xref>, <xref ref-type="fig" rid="pone.0217091.g002">Fig 2A–2G</xref>). Compared to placebo, BCG induced modest, but statistically significantly higher frequencies of Mtb-lysate-specific CD4+ T cells producing IFNγ, TNFα and IL2 and of CD4+ T cells expressing any combination of cytokines within the Th1 and Th17 related cytokines.</p>
                <fig id="pone.0217091.g002" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0217091.g002</object-id>
                  <label>Fig 2</label>
                  <caption>
                    <title>Total CD4+ T cell cytokine positive production by DAR-901, BCG and placebo vaccinated individuals in response to Mtb lysate stimulation at various study timepoints.</title>
                    <p>CD4+ T cell expression of IFNγ (a), IL2 (b), TNFα (c), IL17(d), IL22 (e) and any IFNγ+, IL2+,TNFα+ cytokine (f) and any IFNγ+, IL2+,IL17+,IL22+ cytokine (g) in response to Mtb lysate stimulant in the DAR-901 (n = 10), BCG (n = 9) and Placebo (n = 9) vaccinated subject was assessed. The median CD4+ T cell cytokine responses (+IQR) are shown at each visit, after subtraction of the unstimulated levels. Treatment-specific immune responses were calculated by AUC analyses for the longitudinal immune responses for individual participants within each treatment group. The Kruskal-Wallis test (with Dunn’s post hoc test) was used to assess for differences between groups from 7-days until 180-days post dose 3 in total cytokine-producing CD4+ T cells (results shown above). Total median cytokine producing CD4+ T cell responses were compared for differences at baseline, at 7-days post dose 3 and at 180-days post dose 3) using Wilcoxon signed-rank test (results shown in <xref ref-type="supplementary-material" rid="pone.0217091.s001">S1 Table</xref>).</p>
                  </caption>
                  <graphic xlink:href="pone.0217091.g002"/>
                </fig>
              </sec>
              <sec id="sec015">
                <title>DAR-901 induces low frequencies of antigen-specific polyfunctional/bifunctional CD4+ T cells</title>
                <p>Since the DAR-901-induced CD4+ T cells to antigen re-stimulation response was only significant in the context of Th1 cytokines and any cytokine responses, we explored the induction of double and triple cytokine producing IFNγ, TNFα and IL2 CD4+ T cell responses to DAR-901 lysate (<xref ref-type="fig" rid="pone.0217091.g003">Fig 3</xref>; <xref ref-type="supplementary-material" rid="pone.0217091.s005">S3 Fig</xref>).</p>
                <fig id="pone.0217091.g003" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0217091.g003</object-id>
                  <label>Fig 3</label>
                  <caption>
                    <title>Longitudinal kinetics of DAR-901 lysate-specific CD4+ T cell responses in the DAR-901 compared to placebo vaccinated subjects.</title>
                    <p>Plotted graphs represent the median for each group after subtraction of background responses, and error bars represent the IQR. Frequencies of DAR-901 lysate-specific CD4+ T cells co-expressing IFNγ, TNFα and IL2 (a) or combinations between IFNγ, TNFα, IL2 (b,c,d) at each timepoint is shown for each treatment group (DAR-901 n = 10; Placebo n = 9). For each CD4+ T cell subset the AUC was compared using Mann-Whitney U test for differences between placebo and DAR-901 treatment groups (results shown above), whilst Wilcoxon signed-rank test was used for comparison of median responses at baseline versus all post-dose 3 timepoints within the DAR-901 vaccinated group (results shown in <xref ref-type="supplementary-material" rid="pone.0217091.s002">S2 Table</xref>).</p>
                  </caption>
                  <graphic xlink:href="pone.0217091.g003"/>
                </fig>
                <p>Among recipients of DAR-901, compared to baseline, responses to DAR-901 antigen at 7-days post-dose 3 were significantly increased, including for CD4+ bifunctional T cells producing IFNγ+ and IL2+ (p = 0.0039, Wilcoxon signed rank test) (<xref ref-type="fig" rid="pone.0217091.g003">Fig 3D</xref>; see <xref ref-type="supplementary-material" rid="pone.0217091.s002">S2 Table</xref> for inter-group comparison). At 180-dayss post dose 3, these polyfunctional and bifunctional CD4+ T cell responses had waned to frequencies similar to baseline (<xref ref-type="fig" rid="pone.0217091.g003">Fig 3A–3D</xref>; <xref ref-type="supplementary-material" rid="pone.0217091.s002">S2 Table</xref> ). Bifunctional and polyfunctional CD4+ T cell cytokine responses to Mtb lysate and DAR-901 lysate did not differ between placebo and vaccine conditions (<xref ref-type="fig" rid="pone.0217091.g003">Fig 3A–3D</xref>; <xref ref-type="supplementary-material" rid="pone.0217091.s005">S3 Fig</xref>).</p>
              </sec>
              <sec id="sec016">
                <title>The CD4+ T cell response to DAR-901 consists predominantly of polyfunctional cells producing IFNγ+TNFα+IL2+</title>
                <p>We characterized the proportion of DAR-901-vaccine specific CD4+ T cell cytokine responses that consisted of single cytokine responses or bifunctional and polyfunctional responses. To do this, we determined the relative proportion (median) of polyfunctional CD4+ subsets using the Boolean function within panels representing Th1 cytokines and another including Th1/Th17/Th22 cytokines.</p>
                <p>DAR-901 induced CD4+ responses consisted predominantly of polyfunctional combination of IFNγ+TNFα+IL2+ producing T cells which were sustained until the end-of-vaccine phase (<xref ref-type="fig" rid="pone.0217091.g004">Fig 4A</xref>). Although there was no substantial increase in frequencies of T cells producing Th17/Th22 related cytokines, by the end of the study a small proportion of IL22-only producing T cells is evident (<xref ref-type="fig" rid="pone.0217091.g004">Fig 4B</xref>). Consistent with previous literature, BCG responses to the BCG antigen consisted mostly of polyfunctional combinations of IFNγ+TNFα+IL2+, IFNγ+TNFα+IL2- and IFNγ+ only producing T cells. Combinations of IFNγ+TNFα+IL2+ and IFNγ+TNFα+IL2- gradually increased by the end-of-vaccine phase, whilst single-producing IFNγ+ responses decreased substantially (<xref ref-type="fig" rid="pone.0217091.g004">Fig 4A</xref>).</p>
                <fig id="pone.0217091.g004" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0217091.g004</object-id>
                  <label>Fig 4</label>
                  <caption>
                    <title>CD4+ T cell functional profiles of vaccine specific responses in DAR-901 and BCG vaccinated individuals.</title>
                    <p>Side to side comparison of DAR-901 responses to DAR-901 lysate (n = 10) and BCG responses to BCG stimulant (n = 9). Pie charts represent relative proportions of respectivevaccine-specific CD4+ T cells co-producing combinations of A) IFNγ, TNFα and IL2, and B) combinations of IFNγ, IL2, IL17 and IL22 among the DAR-901 and BCG vaccinated subjects at the peak (7-days post-dose 3) and final time point (180-days post-dose 3). Frequencies of each gate were determined using Boolean gating. DAR-901 vaccine responses predominantly comprise of polyfunctional combinations of IFNγ+TNFα+IL2+ producing CD4+ T cells which were sustained until the final study point (Key: G = IFNγ, 2 = IL2, T = TNFα, 17 = IL17, 22 = IL22).</p>
                  </caption>
                  <graphic xlink:href="pone.0217091.g004"/>
                </fig>
              </sec>
              <sec id="sec017">
                <title>DAR-901 vaccine-specific responses CD4+ T cells with a polyfunctional combination of IFNγ+TNFα+IL2+ producing CD4+ T cells were predominantly defined as terminally effector memory cells</title>
                <p>We further compared the peak and end of study responses among DAR-901 and BCG recipients for the memory phenotype of the predominant vaccine-specific IFNγ+TNFα+IL2+ producing CD4+ T cells.</p>
                <p>First, we interrogated memory differentiation state of Mtb- specific CD4+ IFNγ+TNFα+IL2+ T cells at the peak (7-days post-dose 3 and final end point of the vaccine phase (180-days post-dose 3) (<xref ref-type="fig" rid="pone.0217091.g005">Fig 5A and 5B</xref> respectively). Mtb-specific responses in both vaccines showed predominantly an effector memory phenotype both at early and end-of study timepoints. Frequencies of T<sub>EM</sub> phenotype were significantly lower in the DAR-901 recipients compared to BCG recipients. At end of vaccine phase (180-days post-dose 3), but not at earlier time points (<xref ref-type="fig" rid="pone.0217091.g005">Fig 5C</xref>), DAR-901-specific polyfunctional CD4+ responder cells exhibited a terminally differentiated effector memory phenotype in DAR-901 recipients compared to BCG recipients (<xref ref-type="fig" rid="pone.0217091.g005">Fig 5D</xref>).</p>
                <fig id="pone.0217091.g005" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0217091.g005</object-id>
                  <label>Fig 5</label>
                  <caption>
                    <title>Memory phenotype of MTB and vaccine-specific CD4+ IFNγ+TNFα+IL2+ T- cell responses induced by either DAR-901 vaccine or BCG at 7 days and 180-dayss post-dose 3.</title>
                    <p>Memory differentiation state was based on CD45RO versus CCR7 expression to distinguish between naïve T cells, central memory (T<sub>CM</sub>), effector memory (T<sub>EM</sub>) and T cell effector memory re-expressing CD45RA/terminally differentiated effector memory (T<sub>EMRA</sub>) populations. Box plots represent the T cell memory proportions comparing the frequency of vaccine-elicited CD4 memory T cells in peripheral blood in response to DAR-901 and BCG antigen re-stimulation for the respective vaccinated group. Statistical comparison using Mann-Whitney U test was used to determine the significance of differences in the proportions of memory CD4+ T cells between the two treatment groups (DAR-901 n = 10, BCG n = 9).</p>
                  </caption>
                  <graphic xlink:href="pone.0217091.g005"/>
                </fig>
              </sec>
            </sec>
            <sec sec-type="conclusions" id="sec018">
              <title>Discussion</title>
              <p>In a Phase 1 trial we found that three doses of whole cell inactivated DAR-901 immunization elicited polyfunctional Th1-type CD4+ T cell responses to the non-tuberculous mycobacterial vaccine antigen but not to Mtb lysate. DAR-901-specific responder cells exhibited predominantly an effector memory phenotype. DAR-901 represents the same inactivated non-tuberculous mycobacterial strain as SRL172 which was associated with protection from TB in an earlier Phase 3 randomized placebo-controlled double-blind clinical trial[<xref rid="pone.0217091.ref011" ref-type="bibr">11</xref>]. SRL172 induced IFNγ responses to the vaccine antigen and antibody to Mtb LAM but CD4+ T cell specific cytokine responses were not assessed [<xref rid="pone.0217091.ref006" ref-type="bibr">6</xref>,<xref rid="pone.0217091.ref013" ref-type="bibr">13</xref>].</p>
              <p>Previous publications have reported that IFNγ-producing and bifunctional/polyfunctional CD4+ T cells are associated with protection from tuberculosis in experimental models [<xref rid="pone.0217091.ref020" ref-type="bibr">20</xref>,<xref rid="pone.0217091.ref021" ref-type="bibr">21</xref>,<xref rid="pone.0217091.ref026" ref-type="bibr">26</xref>–<xref rid="pone.0217091.ref032" ref-type="bibr">32</xref>]. These associations have not, however, been established in the context of a human prospective vaccine trial. Importantly, the only new candidate vaccine known to elicit human polyfunctional CD4+ T cell cytokine responses–MVA85A –did not confer protection against TB in a Phase 2 clinical trial in BCG-primed South African infants [<xref rid="pone.0217091.ref043" ref-type="bibr">43</xref>]. Various phenotypic and functional attributes of T cells such as recognition of an Mtb-infected cell, trafficking to the lung, and differentiation state as well as long-term memory and survival capacity been hypothesized to be central to human vaccine-mediated protection from TB, but these hypotheses have yet to be confirmed in prospective human vaccine studies.</p>
              <p>Our data are congruent with the prior finding that DAR-901 immunization elicits IFNγ responses assessed by an ELISA platform [<xref rid="pone.0217091.ref017" ref-type="bibr">17</xref>]. Interestingly, we have previously found that baseline IFNγ responses to mycobacterial antigens correlate with protection from HIV-associated TB among placebo recipients in the Phase 3 trial of SRL172 whereas post-immunization IFNγ responses did not correlate with vaccine mediated protection in the same study [<xref rid="pone.0217091.ref005" ref-type="bibr">5</xref>,<xref rid="pone.0217091.ref013" ref-type="bibr">13</xref>,<xref rid="pone.0217091.ref048" ref-type="bibr">48</xref>]. This raises the possibility that natural TB or non-TB mycobacterial exposure together with remote BCG-induced immune protection from TB in adults may be different from booster-mediated protection from TB and thus require different methods of assessment.</p>
              <p>Recent animal studies have suggested that Th17/Th22 cytokine production is an important and novel component of immune protection to TB [<xref rid="pone.0217091.ref019" ref-type="bibr">19</xref>,<xref rid="pone.0217091.ref028" ref-type="bibr">28</xref>,<xref rid="pone.0217091.ref035" ref-type="bibr">35</xref>,<xref rid="pone.0217091.ref037" ref-type="bibr">37</xref>,<xref rid="pone.0217091.ref042" ref-type="bibr">42</xref>]. In this study, we found that neither DAR-901 nor BCG immunization elicited statistically significant Th17/Th22 cytokine responses. Of note, M72/AS01<sub>E</sub> induced low-level vaccine-specific Th17 responses early after vaccination [<xref rid="pone.0217091.ref015" ref-type="bibr">15</xref>].As with Th1 type CD4+ T cell cytokine responses, further study is required to determine whether Th17/Th22 cytokine responses are relevant to vaccine-induced immunity to TB in humans.</p>
              <p>Strengths of this study include its prospective longitudinal follow up and assessment of a panel of multiple T cell cytokine responses to DAR-901 and other antigens. We observed clear and consistent differences in DAR-901-specific CD4+ T cell IFNγ+ and polyfunctional responses between baseline and later time points. We did not observe statistically significant differences in DAR-901-specific cytokine responses at any time point between DAR-901 and placebo recipients. This is likely because the study was underpowered to detect small differences in cytokine responses between the 10 concurrent vaccine recipients and the pool of 9 placebo recipients representing 3 subjects from the sequential three arms of this dose escalation study. DAR-901 immunization also did not induce cytokine responses to Mtb lysate when later time points were compared to baseline or in comparisons of DAR-901 recipients to placebo control. Taken together these data indicate that DAR-901 vaccination elicits low frequencies of short-lived bifunctional and polyfunctional CD4+ T cell cytokine responses to the non-tuberculous mycobacterial vaccine antigen but not Mtb lysate.</p>
              <p>In contrast, and as expected, BCG booster recipients did exhibit greater CD4+ T cell cytokine responses to Mtb lysate at multiple time points. Since BCG booster vaccination has not been associated with improved protection from TB disease, as seen in previous clinical trials in Brazil and Malawi, [<xref rid="pone.0217091.ref009" ref-type="bibr">9</xref>,<xref rid="pone.0217091.ref010" ref-type="bibr">10</xref>,<xref rid="pone.0217091.ref023" ref-type="bibr">23</xref>,<xref rid="pone.0217091.ref049" ref-type="bibr">49</xref>,<xref rid="pone.0217091.ref050" ref-type="bibr">50</xref>], these data highlight the challenge of correlating detectable vaccine-related changes in immune responses to meaningful protection from TB disease. We did not observe substantial or sustained Th17/Th22 responses, either because the vaccine does not elicit such responses, or they are not well-detected in peripheral blood specimens.</p>
              <p>Given uncertainty regarding whether large numbers of IFNγ producing T cells (Th1 response) or other CD4+ T cell cytokine responses are associated with immune protection from TB disease, it will be important to explore different types of immune responses to TB vaccine candidates [<xref rid="pone.0217091.ref051" ref-type="bibr">51</xref>]. Innate immune responses have not been extensively explored in TB vaccine-related clinical trials, nor in our current study. A recent study in rhesus macaques has demonstrated that neutrophil degranulation and other innate immune responses correlated with protection from TB disease in a subset of monkeys with mild disease [<xref rid="pone.0217091.ref034" ref-type="bibr">34</xref>]. This finding, and others, highlight the importance of examining immune responses in non-traditional cell types and perhaps even to under-investigated antigens. DAR-901 is currently being investigated for efficacy in reducing Mtb infection in a Phase 2b clinical trial among adolescents in Tanzania. We plan to explore whole blood transcriptomic responses in this trial, which will allow us to explore myeloid and lymphocyte signatures associated with susceptibility/resistance to infection.</p>
            </sec>
            <sec sec-type="conclusions" id="sec019">
              <title>Conclusion</title>
              <p>DAR-901, a TB booster vaccine grown from the master cell bank of SRL 172, a vaccine that was shown to prevent TB and to be safe and effective in a Phase 3 trial, has the potential to be an effective booster for BCG in adults and children living in tuberculosis-endemic countries. The present study has shown that DAR-901 induces low magnitude polyfunctional effector memory CD4+ T cell responses. DAR-901 responses were lower than those induced by BCG, a vaccine that has been shown ineffective as a booster to prevent tuberculosis disease. These observations suggest that induction of higher levels of CD4+ cytokine stimulation may not be a critical or pre-requisite characteristic for a candidate TB vaccine booster. A broader interrogation of immune response should be included in future clinical trials of candidate TB vaccine boosters.</p>
            </sec>
            <sec sec-type="supplementary-material" id="sec020">
              <title>Supporting information</title>
              <supplementary-material content-type="local-data" id="pone.0217091.s001">
                <label>S1 Table</label>
                <caption>
                  <title>Total cytokine comparison within the DAR-901 vaccinated subjects at baseline and at 7-days and 180-days post-dose 3 timepoints.</title>
                  <p>Wilcoxon signed-rank test was used to assess differences between median responses.</p>
                  <p>(DOCX)</p>
                </caption>
                <media xlink:href="pone.0217091.s001.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material content-type="local-data" id="pone.0217091.s002">
                <label>S2 Table</label>
                <caption>
                  <title>Median combinatorial cytokine responses within the DAR-901 and placebo treatment groups vaccine-specific cytokine producing CD4+ T cells during baseline and all the post-dose 3 timepoints.</title>
                  <p>Polyfunctional and bifunctional combinations of IFN<italic>γ</italic>, TNFα and IL2 cytokine producing T cells within the DAR-901 vaccinated group (n = 10) and placebo group (n = 9) was calculated. Wilcoxon signed rank test was used to assess differences between median responses.</p>
                  <p>(DOCX)</p>
                </caption>
                <media xlink:href="pone.0217091.s002.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material content-type="local-data" id="pone.0217091.s003">
                <label>S1 Fig</label>
                <caption>
                  <title>CONSORT flow chart for the DAR-901 clinical trial.</title>
                  <p>The present study focused on a subset of IGRA-negative subjects in the randomized dose escalation groups (cohort A1-A3) and included a total of 28 subjects: the 10 recipients of the three 1.0mg intradermal dose of DAR-901 (A3 cohort, the dose that has been selected for further clinical trials), the pool of 9 subjects (3 each in dose escalation cohorts A1-A3) who received 3 intradermal doses of saline placebo, and the pool of 9 subjects who received two dose of saline followed by a single intradermal dose of BCG.</p>
                  <p>(DOC)</p>
                </caption>
                <media xlink:href="pone.0217091.s003.doc">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material content-type="local-data" id="pone.0217091.s004">
                <label>S2 Fig</label>
                <caption>
                  <title>Total cytokine positive production by DAR-901, BCG and placebo vaccinated individuals in response to DAR-901 lysate stimulation at various study timepoints.</title>
                  <p>Cytokine producing IFN<italic>γ</italic> (a), IL2 (b), TNFα (c), IL17 (e) and IL22 (f) T cells and a combination of any IFN<italic>γ</italic>+, IL2+,TNFα+ cytokine(d) and any IFN<italic>γ</italic>+, IL2+,IL17+,IL22+ cytokine(g) cytokine response to DAR-901 lysate stimulant in the DAR-901- (n = 10), BCG- (n = 9) and Placebo- (n = 9) vaccinated subjects was assessed (total n = 28). The median cytokine responses (+IQR) are shown at each visit, after subtraction of the unstimulated levels. Treatment specific immune responses AUC analyses are calculated for the longitudinal immune responses for individual participants for all the post-dose 3 timepoints for the respective treatment group. The Kruskal-Wallis test (with Dunn’s post hoc test) was used to assess for differences between groups in total cytokine producing T cells. Total median cytokine producing T cell responses were compared for differences at baseline, 7-days and 180-days post-dose 3 using Wilcoxon signed-rank test (results shown in <xref ref-type="supplementary-material" rid="pone.0217091.s001">S1 Table</xref>).</p>
                  <p>(TIF)</p>
                </caption>
                <media xlink:href="pone.0217091.s004.tif">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material content-type="local-data" id="pone.0217091.s005">
                <label>S3 Fig</label>
                <caption>
                  <title>Longitudinal kinetics of DAR-901 Mtb-specific CD4+ T cell responses in the DAR-901 vaccinated group compared to the placebo group.</title>
                  <p>Plotted graphs represent the median for each group and error bars represent the IQR, after background was subtracted. Frequencies of DAR-901 Mtb- specific CD4 T cells co-expressing IFN<italic>γ</italic>, TNFα and IL2 or combinations between IFN<italic>γ</italic>, TNFα, IL2 at each timepoint is shown for each treatment group. For each T cell subset the AUC was compared using Mann-Whitney U test for differences between placebo and DAR-901 treatment group (results shown above), whilst Wilcoxon signed-rank test was used for comparison of median responses at baseline versus all post-dose 3 timepoints within the DAR-901 vaccinated group (results shown in <xref ref-type="supplementary-material" rid="pone.0217091.s002">S2 Table</xref>).</p>
                  <p>(TIF)</p>
                </caption>
                <media xlink:href="pone.0217091.s005.tif">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material content-type="local-data" id="pone.0217091.s006">
                <label>S1 File</label>
                <caption>
                  <title>CONSORT checklist.</title>
                  <p>(DOC)</p>
                </caption>
                <media xlink:href="pone.0217091.s006.doc">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack>
              <p>The authors wish to thank our volunteers for the study and the following funders: the Dartmouth College, the Aeras Foundation, the Jack and Dorothy Byrne Foundation, the National Institute for Health Research Health Protection Research Unit in Respiratory Infections at Imperial College London in partnership with Public Health England and the Imperial National Institute for Health Research Health Biomedical Research Centre; for their financial support.</p>
            </ack>
            <ref-list>
              <title>References</title>
              <ref id="pone.0217091.ref001">
                <label>1</label>
                <mixed-citation publication-type="other">WHO. Global Tuberculosis Report. 2017;(2017):1–4.</mixed-citation>
              </ref>
              <ref id="pone.0217091.ref002">
                <label>2</label>
                <mixed-citation publication-type="journal"><name><surname>Gijsel</surname><given-names>D De</given-names></name>, <name><surname>von Reyn</surname><given-names>CF</given-names></name>. <article-title>International Journal of Infectious Diseases A Breath of Fresh Air: BCG Prevents Adult Pulmonary Tuberculosis</article-title>. <source>Int J Infect Dis</source> [Internet]. <year>2019</year>;<volume>80</volume>:<fpage>S6</fpage>–<lpage>8</lpage>. Available from: <pub-id pub-id-type="doi">10.1016/j.ijid.2019.02.036</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0217091.ref003">
                <label>3</label>
                <mixed-citation publication-type="journal"><name><surname>Schrager</surname><given-names>LK</given-names></name>, <name><surname>Harris</surname><given-names>RC</given-names></name>, <name><surname>Vekemans</surname><given-names>J</given-names></name>, <name><surname>Zenteno-cuevas</surname><given-names>R</given-names></name>. <article-title>Research and development of new tuberculosis vaccines:: a review</article-title>. <source>F1000Research</source>. <year>2018</year>;<volume>7</volume>:<fpage>1732</fpage><pub-id pub-id-type="doi">10.12688/f1000research.16521.2</pub-id><?supplied-pmid 30613395?><pub-id pub-id-type="pmid">30613395</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0217091.ref004">
                <label>4</label>
                <mixed-citation publication-type="journal"><name><surname>Knight</surname><given-names>GM</given-names></name>, <name><surname>Griffiths</surname><given-names>UK</given-names></name>, <name><surname>Sumner</surname><given-names>T</given-names></name>, <name><surname>Laurence Y</surname><given-names>V</given-names></name>, <name><surname>Gheorghe</surname><given-names>A</given-names></name>, <name><surname>Vassall</surname><given-names>A</given-names></name>, <etal>et al</etal><article-title>Impact and cost-effectiveness of new tuberculosis vaccines in low- and middle-income countries</article-title>. <source>Proc Natl Acad Sci</source>. <year>2014</year>;<volume>111</volume>(<issue>43</issue>).</mixed-citation>
              </ref>
              <ref id="pone.0217091.ref005">
                <label>5</label>
                <mixed-citation publication-type="journal"><name><surname>Lahey</surname><given-names>T</given-names></name>, <name><surname>Sheth</surname><given-names>S</given-names></name>, <name><surname>Matee</surname><given-names>M</given-names></name>, <name><surname>Arbeit</surname><given-names>R</given-names></name>, <name><surname>Horsburgh</surname><given-names>R</given-names></name>, <name><surname>Mtei</surname><given-names>L</given-names></name>, <etal>et al</etal><article-title>Interferon γ Responses to Mycobacterial Antigens Protect against Subsequent HIV‐Associated Tuberculosis</article-title>. <source>J Infect Dis</source>. <year>2010</year>;<volume>202</volume>(<issue>8</issue>):<fpage>1265</fpage>–<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1086/656332</pub-id>
<?supplied-pmid 20812851?><pub-id pub-id-type="pmid">20812851</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0217091.ref006">
                <label>6</label>
                <mixed-citation publication-type="journal"><name><surname>Lahey</surname><given-names>T</given-names></name>, <name><surname>Arbeit</surname><given-names>RD</given-names></name>, <name><surname>Bakari</surname><given-names>M</given-names></name>, <name><surname>Horsburgh</surname><given-names>CR</given-names></name>, <name><surname>Matee</surname><given-names>M</given-names></name>, <name><surname>Waddell</surname><given-names>R</given-names></name>, <etal>et al</etal><article-title>Immunogenicity of a protective whole cell mycobacterial vaccine in HIV-infected adults: A phase III study in Tanzania</article-title>. <source>Vaccine</source> [Internet]. <year>2010</year>;<volume>28</volume>(<issue>48</issue>):<fpage>7652</fpage>–<lpage>8</lpage>. Available from: <pub-id pub-id-type="doi">10.1016/j.vaccine.2010.09.041</pub-id>
<?supplied-pmid 20875492?><pub-id pub-id-type="pmid">20875492</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0217091.ref007">
                <label>7</label>
                <mixed-citation publication-type="journal"><name><surname>Andrews</surname><given-names>JR</given-names></name>, <name><surname>Hatherill</surname><given-names>M</given-names></name>, <name><surname>Mahomed</surname><given-names>H</given-names></name>, <name><surname>Hanekom</surname><given-names>WA</given-names></name>, <name><surname>Campo</surname><given-names>M</given-names></name>, <name><surname>Hawn</surname><given-names>TR</given-names></name>, <etal>et al</etal><article-title>The dynamics of QuantiFERON-TB Gold in-Tube conversion and reversion in a cohort of South African adolescents</article-title>. <source>Am J Respir Crit Care Med</source>. <year>2015</year>;<volume>191</volume>(<issue>5</issue>):<fpage>584</fpage>–<lpage>91</lpage>. <pub-id pub-id-type="doi">10.1164/rccm.201409-1704OC</pub-id>
<?supplied-pmid 25562578?><pub-id pub-id-type="pmid">25562578</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0217091.ref008">
                <label>8</label>
                <mixed-citation publication-type="journal"><name><surname>Roy</surname><given-names>A</given-names></name>, <name><surname>Eisenhut</surname><given-names>M</given-names></name>, <name><surname>Harris</surname><given-names>RJ</given-names></name>, <name><surname>Rodrigues</surname><given-names>LC</given-names></name>, <name><surname>Sridhar</surname><given-names>S</given-names></name>, <name><surname>Habermann</surname><given-names>S</given-names></name>, <etal>et al</etal><article-title>Effect of BCG vaccination against Mycobacterium tuberculosis infection in children: Systematic review and meta-analysis</article-title>. <source>BMJ</source>. <year>2014</year>;<volume>349</volume>(<month>8</month>):<fpage>1</fpage>–<lpage>11</lpage>.</mixed-citation>
              </ref>
              <ref id="pone.0217091.ref009">
                <label>9</label>
                <mixed-citation publication-type="journal"><name><surname>Rodrigues</surname><given-names>LC</given-names></name>, <name><surname>Pereira</surname><given-names>SM</given-names></name>, <name><surname>Cunha</surname><given-names>SS</given-names></name>, <name><surname>Genser</surname><given-names>B</given-names></name>, <name><surname>Ichihara</surname><given-names>MY</given-names></name>, <name><surname>Brito</surname><given-names>SC De</given-names></name>, <etal>et al</etal><article-title>Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: the BCG-REVAC cluster-randomised trial</article-title>. <source>Lancet</source>. <year>2005</year>;<volume>366</volume>(<issue>9493</issue>):<fpage>1290</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(05)67145-0</pub-id>
<?supplied-pmid 16214599?><pub-id pub-id-type="pmid">16214599</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0217091.ref010">
                <label>10</label>
                <mixed-citation publication-type="journal"><name><surname>Fine</surname><given-names>PEM</given-names></name>. <article-title>Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi</article-title>. <source>Lancet</source>. <year>1996</year>;<volume>348</volume>(<issue>9019</issue>):<fpage>17</fpage>–<lpage>24</lpage>. <?supplied-pmid 8691924?><pub-id pub-id-type="pmid">8691924</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0217091.ref011">
                <label>11</label>
                <mixed-citation publication-type="journal"><name><surname>Nemes</surname><given-names>E</given-names></name>, <name><surname>Geldenhuys</surname><given-names>H</given-names></name>, <name><surname>Rozot</surname><given-names>V</given-names></name>, <name><surname>Rutkowski</surname><given-names>KT</given-names></name>, <name><surname>Ratangee</surname><given-names>F</given-names></name>, <name><surname>Bilek</surname><given-names>N</given-names></name>, <etal>et al</etal><article-title>Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination</article-title>. <source>N Engl J Med</source> [Internet]. <year>2018</year>;<volume>379</volume>(<issue>2</issue>):<fpage>138</fpage>–<lpage>49</lpage>. Available from: <pub-id pub-id-type="doi">10.1056/NEJMoa1714021</pub-id>
<?supplied-pmid 29996082?><pub-id pub-id-type="pmid">29996082</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0217091.ref012">
                <label>12</label>
                <mixed-citation publication-type="book"><name><surname>Ginsberg</surname><given-names>A.</given-names></name>, <name><surname>Churchyard</surname><given-names>G.</given-names></name>, <name><surname>Dieffenbach</surname><given-names>C.</given-names></name>, <name><surname>Hatherhill</surname><given-names>M.</given-names></name> and <name><surname>Gurunathan</surname><given-names>S</given-names></name>. <source>H4:IC31/BCG Revaccination POI Trial Results</source>. [online] <publisher-loc>New Delhi, India</publisher-loc>, <publisher-name>5th Globla Forum on TB Vaccines</publisher-name>
<year>2018</year>; Available from: <ext-link ext-link-type="uri" xlink:href="https://www.youtube.com/watch?v=j4Iqvau5cpQ&amp;t=21s">https://www.youtube.com/watch?v=j4Iqvau5cpQ&amp;t=21s</ext-link></mixed-citation>
              </ref>
              <ref id="pone.0217091.ref013">
                <label>13</label>
                <mixed-citation publication-type="journal"><name><surname>von Reyn</surname><given-names>CF</given-names></name>, <name><surname>Mtei</surname><given-names>L</given-names></name>, <name><surname>Arbeit</surname><given-names>RD</given-names></name>, <name><surname>Waddell</surname><given-names>R</given-names></name>, <name><surname>Cole</surname><given-names>B</given-names></name>, <name><surname>Mackenzie</surname><given-names>T</given-names></name>, <etal>et al</etal><article-title>Prevention of tuberculosis in Bacille-Guérin-primed, HIV-infected adults boosted Calmette–Gue with an inactivated whole-cell mycobacterial vaccine</article-title>. <source>AIDS</source>. <year>2010</year>;<volume>24</volume>(<issue>5</issue>):<fpage>675</fpage>–<lpage>85</lpage>. <pub-id pub-id-type="doi">10.1097/QAD.0b013e3283350f1b</pub-id>
<?supplied-pmid 20118767?><pub-id pub-id-type="pmid">20118767</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0217091.ref014">
                <label>14</label>
                <mixed-citation publication-type="journal"><name><surname>Van Der Meeren</surname><given-names>O.</given-names></name>, <name><surname>Hatherill</surname><given-names>M.</given-names></name>, <name><surname>Nduba</surname><given-names>V.</given-names></name>, <name><surname>Wilkinson</surname><given-names>R.</given-names></name>, <name><surname>Muyoyeta</surname><given-names>M.</given-names></name>, <name><surname>Van Brakel</surname><given-names>E.</given-names></name>, <name><surname>Ayles</surname><given-names>H.</given-names></name>, <name><surname>Henostroza</surname><given-names>G.</given-names></name>, <name><surname>Thienemann</surname><given-names>F.</given-names></name>, <name><surname>Scriba</surname><given-names>T.</given-names></name>, <name><surname>Diacon</surname><given-names>A.</given-names></name>, <name><surname>Blatner</surname><given-names>G.</given-names></name>, <name><surname>Demoitié</surname><given-names>M.</given-names></name>, <name><surname>Tameris</surname><given-names>M.</given-names></name>, <name><surname>Malahleha</surname><given-names>M.</given-names></name>, <name><surname>Innes</surname><given-names>J.</given-names></name>, <name><surname>Hellström</surname><given-names>E.</given-names></name>, <name><surname>Martinson</surname><given-names>N.</given-names></name>, <article-title>S D. Phase 2b Controlled Trial of M72/AS01 E Vaccine to Prevent Tuberculosis</article-title>. <source>N Engl J Med</source>. <year>2018</year>;<volume>379</volume>(<issue>17</issue>):<fpage>1621</fpage>–<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1803484</pub-id>
<?supplied-pmid 30280651?><pub-id pub-id-type="pmid">30280651</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0217091.ref015">
                <label>15</label>
                <mixed-citation publication-type="journal"><name><surname>Penn-Nicholson</surname><given-names>A.</given-names></name>, <name><surname>Geldenhuys</surname><given-names>H.</given-names></name>, <name><surname>Burny</surname><given-names>W.</given-names></name>, <name><surname>van der Most</surname><given-names>R.</given-names></name>, <name><surname>Day</surname><given-names>C.</given-names></name>, <name><surname>Jongert</surname><given-names>E.</given-names></name>, <name><surname>Moris</surname><given-names>P.</given-names></name>, <name><surname>Hatherill</surname><given-names>M.</given-names></name>, <name><surname>Ofori-Anyinam</surname><given-names>O.</given-names></name>, <name><surname>Hanekom</surname><given-names>W.</given-names></name>, <name><surname>Bollaerts</surname><given-names>A.</given-names></name>, <name><surname>Demoitie</surname><given-names>M.</given-names></name>, <name><surname>Kany Luabeya</surname><given-names>A.</given-names></name>, <name><surname>De Ruymaeker</surname><given-names>E.</given-names></name>, <name><surname>Tameris</surname><given-names>M.</given-names></name>, <name><surname>Lapierre</surname><given-names>D.</given-names></name> and <article-title>Scriba T. Safety and immunogenicity of candidate vaccine M72/AS01E in adolescents in a TB endemic setting</article-title>. <source>Vaccine</source>. <year>2015</year>;<volume>33</volume>(<issue>32</issue>):<fpage>4025</fpage>–<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2015.05.088</pub-id>
<?supplied-pmid 26072017?><pub-id pub-id-type="pmid">26072017</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0217091.ref016">
                <label>16</label>
                <mixed-citation publication-type="journal"><name><surname>Lahey</surname><given-names>T</given-names></name>, <name><surname>Laddy</surname><given-names>D</given-names></name>, <name><surname>Hill</surname><given-names>K</given-names></name>, <name><surname>Schaeffer</surname><given-names>J</given-names></name>, <name><surname>Hogg</surname><given-names>A</given-names></name>, <name><surname>Keeble</surname><given-names>J</given-names></name>, <etal>et al</etal><article-title>Immunogenicity and Protective Efficacy of the DAR-901 Booster Vaccine in a Murine Model of Tuberculosis</article-title>. <source>PLoS One</source>. <year>2016</year>;<volume>11</volume>(<issue>12</issue>):<fpage>1</fpage>–<lpage>12</lpage>.</mixed-citation>
              </ref>
              <ref id="pone.0217091.ref017">
                <label>17</label>
                <mixed-citation publication-type="journal"><name><surname>von Reyn</surname><given-names>CF</given-names></name>, <name><surname>Lahey</surname><given-names>T</given-names></name>, <name><surname>Arbeit</surname><given-names>RD</given-names></name>, <name><surname>Landry</surname><given-names>B</given-names></name>, <name><surname>Kailani</surname><given-names>L</given-names></name>, <name><surname>Adams L</surname><given-names>V</given-names></name>, <etal>et al</etal><article-title>Safety and immunogenicity of an inactivated whole cell tuberculosis vaccine booster in adults primed with BCG: A randomized, controlled trial of DAR-901</article-title>. <source>PLoS One</source> [Internet]. <year>2017</year>;<volume>12</volume>(<issue>5</issue>):<fpage>1</fpage>–<lpage>16</lpage>. Available from: <pub-id pub-id-type="doi">10.1371/journal.pone.0175215</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0217091.ref018">
                <label>18</label>
                <mixed-citation publication-type="journal"><name><surname>Flynn</surname><given-names>JL</given-names></name>, <name><surname>Chan</surname><given-names>J</given-names></name>. <article-title>Tuberculosis: Latency and Reactivation minireview Tuberculosis</article-title>: <source>Latency and Reactivation</source>. <year>2001</year>;<volume>69</volume>(<issue>7</issue>):<fpage>4195</fpage>–<lpage>201</lpage>.</mixed-citation>
              </ref>
              <ref id="pone.0217091.ref019">
                <label>19</label>
                <mixed-citation publication-type="journal"><name><surname>Wareham</surname><given-names>AS</given-names></name>, <name><surname>Tree</surname><given-names>JA</given-names></name>, <name><surname>Marsh</surname><given-names>PD</given-names></name>, <name><surname>Butcher</surname><given-names>PD</given-names></name>, <name><surname>Dennis</surname><given-names>M</given-names></name>, <name><surname>Sharpe</surname><given-names>SA</given-names></name>. <article-title>Evidence for a Role for Interleukin-17, Th17 Cells and Iron Homeostasis in Protective Immunity against Tuberculosis in Cynomolgus Macaques</article-title>. <source>PLoS One</source>. <year>2014</year>;<volume>9</volume>(<issue>2</issue>):<fpage>1</fpage>–<lpage>11</lpage>.</mixed-citation>
              </ref>
              <ref id="pone.0217091.ref020">
                <label>20</label>
                <mixed-citation publication-type="journal"><name><surname>Fletcher</surname><given-names>HA</given-names></name>, <name><surname>Snowden</surname><given-names>MA</given-names></name>, <name><surname>Landry</surname><given-names>B</given-names></name>, <name><surname>Rida</surname><given-names>W</given-names></name>, <name><surname>Satti</surname><given-names>I</given-names></name>, <name><surname>Harris</surname><given-names>SA</given-names></name>, <etal>et al</etal><article-title>T cell activation is an immune correlate of risk in BCG vaccinated infants</article-title>. <source>Nat Commun</source> [Internet]. <year>2016</year>;<volume>7</volume>:<fpage>11290</fpage> Available from: <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/27068708%5Cnhttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC4832066">http://www.ncbi.nlm.nih.gov/pubmed/27068708%5Cnhttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC4832066</ext-link>
<pub-id pub-id-type="doi">10.1038/ncomms11290</pub-id>
<?supplied-pmid 27068708?><pub-id pub-id-type="pmid">27068708</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0217091.ref021">
                <label>21</label>
                <mixed-citation publication-type="journal"><name><surname>Day</surname><given-names>C. L.</given-names></name><article-title>Functional Capacity of Mycobacterium tuberculosis-Specific T Cell Responses in Humans Is Associated with Mycobacterial Load</article-title>. <source>J Immunol</source>. <year>2011</year>;<volume>187</volume>(<issue>5</issue>):<fpage>2222</fpage>–<lpage>32</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1101122</pub-id>
<?supplied-pmid 21775682?><pub-id pub-id-type="pmid">21775682</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0217091.ref022">
                <label>22</label>
                <mixed-citation publication-type="journal"><name><surname>Harari</surname><given-names>A</given-names></name>, <name><surname>Rozot</surname><given-names>V</given-names></name>, <name><surname>Enders</surname><given-names>FB</given-names></name>, <name><surname>Perreau</surname><given-names>M</given-names></name>, <name><surname>Stalder</surname><given-names>JM</given-names></name>, <name><surname>Nicod</surname><given-names>LP</given-names></name>, <etal>et al</etal><article-title>Dominant TNF-α+ Mycobacterium tuberculosis-specific CD4+ T cell responses discriminate between latent infection and active disease</article-title>. <source>Nat Med</source>. <year>2011</year>;<volume>17</volume>(<issue>3</issue>):<fpage>372</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1038/nm.2299</pub-id>
<?supplied-pmid 21336285?><pub-id pub-id-type="pmid">21336285</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0217091.ref023">
                <label>23</label>
                <mixed-citation publication-type="journal"><name><surname>Kagina</surname><given-names>BMN</given-names></name>, <name><surname>Abel</surname><given-names>B</given-names></name>, <name><surname>Scriba</surname><given-names>TJ</given-names></name>, <name><surname>Hughes</surname><given-names>EJ</given-names></name>, <name><surname>Keyser</surname><given-names>A</given-names></name>, <name><surname>Soares</surname><given-names>A</given-names></name>, <etal>et al</etal><article-title>Specific T Cell Frequency and Cytokine Expression Profile Do Not Correlate with Protection against Tuberculosis after Bacillus Calmette-Guérin Vaccination of Newborns</article-title>. <source>Am J Respir Crit Care Med</source>. <year>2010</year>;<volume>182</volume>(<issue>8</issue>):<fpage>1073</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1164/rccm.201003-0334OC</pub-id>
<?supplied-pmid 20558627?><pub-id pub-id-type="pmid">20558627</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0217091.ref024">
                <label>24</label>
                <mixed-citation publication-type="journal"><name><surname>Derrick</surname><given-names>SC</given-names></name>, <name><surname>Yabe</surname><given-names>IM</given-names></name>, <name><surname>Yang</surname><given-names>A</given-names></name>, <name><surname>Morris</surname><given-names>SL</given-names></name>. <article-title>Vaccine-induced anti-tuberculosis protective immunity in mice correlates with the magnitude and quality of multifunctional CD4 T cells</article-title>. <source>Vaccine</source> [Internet]. <year>2011</year>;<volume>29</volume>(<issue>16</issue>):<fpage>2902</fpage>–<lpage>9</lpage>. Available from: <pub-id pub-id-type="doi">10.1016/j.vaccine.2011.02.010</pub-id>
<?supplied-pmid 21338678?><pub-id pub-id-type="pmid">21338678</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0217091.ref025">
                <label>25</label>
                <mixed-citation publication-type="journal"><name><surname>Mittrucker</surname><given-names>H-W</given-names></name>. <article-title>Poor correlation between BCG vaccination-induced T cell responses and protection against tuberculosis</article-title>. <source>Proc Natl Acad Sci</source>. <year>2007</year>;<volume>104</volume>(<issue>30</issue>):<fpage>12434</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0703510104</pub-id>
<?supplied-pmid 17640915?><pub-id pub-id-type="pmid">17640915</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0217091.ref026">
                <label>26</label>
                <mixed-citation publication-type="journal"><name><surname>Forbes</surname><given-names>EK</given-names></name>, <name><surname>Sander</surname><given-names>C</given-names></name>, <name><surname>Ronan</surname><given-names>E</given-names></name>, <name><surname>Mcshane</surname><given-names>H</given-names></name>, <name><surname>Hill</surname><given-names>AVS</given-names></name>, <name><surname>Peter</surname><given-names>CL</given-names></name>, <etal>et al</etal><article-title>Multifunctional, High-Level Cytokine-Producing Th1 Cells in the Lung, but Not Spleen, Correlate with Protection against Mycobacterium tuberculosis Aerosol Challenge in Mice</article-title>. <source>J Immunol</source>. <year>2008</year>;<volume>181</volume>(<issue>7</issue>):<fpage>4955</fpage>–<lpage>64</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.181.7.4955</pub-id>
<?supplied-pmid 18802099?><pub-id pub-id-type="pmid">18802099</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0217091.ref027">
                <label>27</label>
                <mixed-citation publication-type="journal"><name><surname>Aagaard</surname><given-names>C</given-names></name>, <name><surname>Hoang</surname><given-names>T</given-names></name>, <name><surname>Dietrich</surname><given-names>J</given-names></name>, <name><surname>Cardona</surname><given-names>P</given-names></name>, <name><surname>Izzo</surname><given-names>A</given-names></name>, <name><surname>Dolganov</surname><given-names>G</given-names></name>, <etal>et al</etal><article-title>A multistage tuberculosis vaccine that confers efficient protection before and after exposure</article-title>. <source>Nat Med</source> [Internet]. <year>2011</year>;<volume>17</volume>(<issue>2</issue>):<fpage>189</fpage>–<lpage>94</lpage>. Available from: <pub-id pub-id-type="doi">10.1038/nm.2285</pub-id>
<?supplied-pmid 21258338?><pub-id pub-id-type="pmid">21258338</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0217091.ref028">
                <label>28</label>
                <mixed-citation publication-type="journal"><name><surname>Desel</surname><given-names>C</given-names></name>, <name><surname>Dorhoi</surname><given-names>A</given-names></name>, <name><surname>Bandermann</surname><given-names>S</given-names></name>, <name><surname>Grode</surname><given-names>L</given-names></name>, <name><surname>Eisele</surname><given-names>B</given-names></name>, <name><surname>Kaufmann</surname><given-names>SHE</given-names></name>. <article-title>Recombinant BCG DureC hly1 Induces Superior Protection Over Parental BCG by Stimulating a Balanced Combination of Type 1 and Type 17 Cytokine Responses</article-title>. <source>J Infect Dis</source>. <year>2011</year>;<volume>204</volume>(<issue>10</issue>):<fpage>1573</fpage>–<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1093/infdis/jir592</pub-id>
<?supplied-pmid 21933877?><pub-id pub-id-type="pmid">21933877</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0217091.ref029">
                <label>29</label>
                <mixed-citation publication-type="journal"><name><surname>Grode</surname><given-names>L</given-names></name>, <name><surname>Ganoza</surname><given-names>CA</given-names></name>, <name><surname>Brohm</surname><given-names>C</given-names></name>, <name><surname>Weiner</surname><given-names>J</given-names></name>, <name><surname>Eisele</surname><given-names>B</given-names></name>, <name><surname>Kaufmann</surname><given-names>SHE</given-names></name>. <article-title>Safety and immunogenicity of the recombinant BCG vaccine VPM1002 in a phase 1 open-label randomized clinical trial</article-title>. <source>Vaccine</source> [Internet]. <year>2013</year>;<volume>31</volume>(<issue>9</issue>):<fpage>1340</fpage>–<lpage>8</lpage>. Available from: <pub-id pub-id-type="doi">10.1016/j.vaccine.2012.12.053</pub-id>
<?supplied-pmid 23290835?><pub-id pub-id-type="pmid">23290835</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0217091.ref030">
                <label>30</label>
                <mixed-citation publication-type="journal"><name><surname>Geldenhuys</surname><given-names>H</given-names></name>, <name><surname>Mearns</surname><given-names>H</given-names></name>, <name><surname>Miles</surname><given-names>DJC</given-names></name>, <name><surname>Tameris</surname><given-names>M</given-names></name>, <name><surname>Hokey</surname><given-names>D</given-names></name>, <name><surname>Shi</surname><given-names>Z</given-names></name>, <etal>et al</etal><article-title>The tuberculosis vaccine H4: IC31 is safe and induces a persistent polyfunctional CD4 T cell response in South African adults: A randomized controlled trial</article-title>. <source>Vaccine</source> [Internet]. <year>2015</year>;<volume>33</volume>(<issue>30</issue>):<fpage>3592</fpage>–<lpage>9</lpage>. Available from: <pub-id pub-id-type="doi">10.1016/j.vaccine.2015.05.036</pub-id>
<?supplied-pmid 26048780?><pub-id pub-id-type="pmid">26048780</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0217091.ref031">
                <label>31</label>
                <mixed-citation publication-type="journal"><name><surname>White</surname><given-names>AD</given-names></name>, <name><surname>Sarfas</surname><given-names>C</given-names></name>, <name><surname>West</surname><given-names>K</given-names></name>, <name><surname>Sibley</surname><given-names>LS</given-names></name>, <name><surname>Wareham</surname><given-names>AS</given-names></name>, <name><surname>Clark</surname><given-names>S</given-names></name>, <etal>et al</etal><article-title>Evaluation of the Immunogenicity of Mycobacterium bovis BCG Delivered by Aerosol to the Lungs of Macaques</article-title>. <source>Clin Vaccine Immunol</source>. <year>2015</year>;<volume>22</volume>(<issue>9</issue>):<fpage>992</fpage>–<lpage>1003</lpage>. <pub-id pub-id-type="doi">10.1128/CVI.00289-15</pub-id>
<?supplied-pmid 26108288?><pub-id pub-id-type="pmid">26108288</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0217091.ref032">
                <label>32</label>
                <mixed-citation publication-type="journal"><name><surname>Maggioli</surname><given-names>MF</given-names></name>, <name><surname>Palmer M</surname><given-names>V</given-names></name>, <name><surname>Thacker</surname><given-names>TC</given-names></name>, <name><surname>Vordermeier</surname><given-names>HM</given-names></name>, <name><surname>Waters</surname><given-names>WR</given-names></name>, <name><surname>Yi</surname><given-names>JS</given-names></name>. <article-title>Increased TNF-α/IFN-γ/IL-2 and Decreased TNF-α/IFN-γ Production by Central Memory T Cells Are Associated with Protective Responses against Bovine Tuberculosis Following BCG Vaccination</article-title>. <source>Front Immunol</source>. <year>2016</year>;<volume>7</volume>:<fpage>1</fpage>–<lpage>18</lpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2016.00001</pub-id><pub-id pub-id-type="pmid">26834743</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0217091.ref033">
                <label>33</label>
                <mixed-citation publication-type="journal"><name><surname>Darrah</surname><given-names>PA</given-names></name>, <name><surname>Bolton</surname><given-names>DL</given-names></name>, <name><surname>Lackner</surname><given-names>AA</given-names></name>, <name><surname>Kaushal</surname><given-names>D</given-names></name>, <name><surname>Aye</surname><given-names>PP</given-names></name>, <name><surname>Mehra</surname><given-names>S</given-names></name>, <etal>et al</etal><article-title>Aerosol Vaccination with AERAS-402 Elicits Robust Cellular Immune Responses in the Lungs of Rhesus Macaques but Fails To Protect against High-Dose Mycobacterium tuberculosis Challenge</article-title>. <source>J Immunol</source>. <year>2014</year>;<volume>193</volume>(<issue>4</issue>):<fpage>1799</fpage>–<lpage>811</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1400676</pub-id>
<?supplied-pmid 25024382?><pub-id pub-id-type="pmid">25024382</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0217091.ref034">
                <label>34</label>
                <mixed-citation publication-type="journal"><name><surname>Hansen</surname><given-names>SG</given-names></name>, <name><surname>Zak</surname><given-names>DE</given-names></name>, <name><surname>Xu</surname><given-names>G</given-names></name>, <name><surname>Ford</surname><given-names>JC</given-names></name>, <name><surname>Marshall</surname><given-names>EE</given-names></name>, <name><surname>Malouli</surname><given-names>D</given-names></name>, <etal>et al</etal><article-title>Prevention of tuberculosis in rhesus macaques by a cytomegalovirus-based vaccine</article-title>. <source>Nat Publ Gr</source> [Internet]. <year>2018</year>; Available from: <pub-id pub-id-type="doi">10.1038/nm.4473</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0217091.ref035">
                <label>35</label>
                <mixed-citation publication-type="journal"><name><surname>Gopal</surname><given-names>R</given-names></name>, <name><surname>Lin</surname><given-names>Y</given-names></name>, <name><surname>Obermajer</surname><given-names>N</given-names></name>, <name><surname>Slight</surname><given-names>S</given-names></name>, <name><surname>Nuthalapati</surname><given-names>N</given-names></name>, <name><surname>Ahmed</surname><given-names>M</given-names></name>, <etal>et al</etal><article-title>IL-23-dependent IL-17 drives Th1-cell responses following Mycobacterium bovis BCG vaccination</article-title>. <source>Eur J Immunol</source>. <year>2012</year>;<volume>42</volume>(<issue>2</issue>):<fpage>364</fpage>–<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1002/eji.201141569</pub-id>
<?supplied-pmid 22101830?><pub-id pub-id-type="pmid">22101830</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0217091.ref036">
                <label>36</label>
                <mixed-citation publication-type="journal"><name><surname>Cruz</surname><given-names>A</given-names></name>. <article-title>BCG vaccination-induced long-lasting control of Mycobacteriumtuberculosis correlates with the accumulation of a novel population of CD4+IL-17+TNF+IL-2+</article-title><source>T cells. Vaccine</source> [Internet]. <year>2015</year>;<volume>33</volume>(<issue>1</issue>):<fpage>85</fpage>–<lpage>91</lpage>. Available from: <pub-id pub-id-type="doi">10.1016/j.vaccine.2014.11.013</pub-id>
<?supplied-pmid 25448107?><pub-id pub-id-type="pmid">25448107</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0217091.ref037">
                <label>37</label>
                <mixed-citation publication-type="journal"><name><surname>Khader</surname><given-names>SA</given-names></name>, <name><surname>Bell</surname><given-names>GK</given-names></name>, <name><surname>Pearl</surname><given-names>JE</given-names></name>, <name><surname>Fountain</surname><given-names>JJ</given-names></name>, <name><surname>Rangel-moreno</surname><given-names>J</given-names></name>, <name><surname>Cilley</surname><given-names>GE</given-names></name>, <etal>et al</etal><article-title>IL-23 and IL-17 in the establishment of protective pulmonary CD4 + T cell responses after vaccination and during Mycobacterium tuberculosis challenge</article-title>. <source>Nat Immunol</source>. <year>2007</year>;<volume>8</volume>(<issue>4</issue>):<fpage>369</fpage>–<lpage>77</lpage>. <pub-id pub-id-type="doi">10.1038/ni1449</pub-id>
<?supplied-pmid 17351619?><pub-id pub-id-type="pmid">17351619</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0217091.ref038">
                <label>38</label>
                <mixed-citation publication-type="journal"><name><surname>Tadokera</surname><given-names>R</given-names></name>, <name><surname>Wilkinson</surname><given-names>KA</given-names></name>, <name><surname>Meintjes</surname><given-names>GA</given-names></name>, <name><surname>Skolimowska</surname><given-names>KH</given-names></name>, <name><surname>Matthews</surname><given-names>K</given-names></name>, <name><surname>Seldon</surname><given-names>R</given-names></name>, <etal>et al</etal><article-title>Role of the Interleukin 10 Family of Cytokines in Patients With Immune Reconstitution In fl ammatory Syndrome Associated With HIV Infection and Tuberculosis</article-title>. <source>J Infect Dis</source>. <year>2013</year>;<volume>207</volume>(<issue>7</issue>):<fpage>1148</fpage>–<lpage>56</lpage>. <pub-id pub-id-type="doi">10.1093/infdis/jit002</pub-id>
<?supplied-pmid 23303806?><pub-id pub-id-type="pmid">23303806</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0217091.ref039">
                <label>39</label>
                <mixed-citation publication-type="journal"><name><surname>Scriba</surname><given-names>TJ</given-names></name>, <name><surname>Kalsdorf</surname><given-names>B</given-names></name>, <name><surname>Abrahams</surname><given-names>D</given-names></name>, <name><surname>Isaacs</surname><given-names>F</given-names></name>. <article-title>Distinct, specific IL-17 and IL-22-producing CD4 + T cell subsets contribute to the human anti-mycobacterial immune response</article-title>. <source>J Immunol</source>. <year>2008</year>;<volume>180</volume>(<issue>3</issue>):<fpage>1962</fpage>–<lpage>70</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.180.3.1962</pub-id>
<?supplied-pmid 18209095?><pub-id pub-id-type="pmid">18209095</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0217091.ref040">
                <label>40</label>
                <mixed-citation publication-type="journal"><name><surname>Freches</surname><given-names>D</given-names></name>, <name><surname>Korf</surname><given-names>H</given-names></name>, <name><surname>Denis</surname><given-names>O</given-names></name>, <name><surname>Havaux</surname><given-names>X</given-names></name>, <name><surname>Huygen</surname><given-names>K</given-names></name>, <name><surname>Romano</surname><given-names>M</given-names></name>. <article-title>Mice genetically inactivated in interleukin-17a receptor are defective in long-term control of mycobacterium tuberculosis infection</article-title>. <source>Immunology</source>. <year>2013</year>;<volume>140</volume>(<issue>2</issue>):<fpage>220</fpage>–<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1111/imm.12130</pub-id>
<?supplied-pmid 23721367?><pub-id pub-id-type="pmid">23721367</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0217091.ref041">
                <label>41</label>
                <mixed-citation publication-type="journal"><name><surname>Goletti</surname><given-names>D</given-names></name>, <name><surname>Petruccioli</surname><given-names>E</given-names></name>, <name><surname>Joosten</surname><given-names>SA</given-names></name>, <name><surname>Ottenhoff</surname><given-names>THM</given-names></name>. <article-title>Tuberculosis biomarkers: From diagnosis to protection</article-title>. <source>Infect Dis Rep</source>. <year>2016</year>;<volume>8</volume>(<issue>2</issue>):<fpage>24</fpage>–<lpage>32</lpage>.</mixed-citation>
              </ref>
              <ref id="pone.0217091.ref042">
                <label>42</label>
                <mixed-citation publication-type="journal"><name><surname>Behrends</surname><given-names>J</given-names></name>, <name><surname>Renauld</surname><given-names>JC</given-names></name>, <name><surname>Ehlers</surname><given-names>S</given-names></name>, <name><surname>Hölscher</surname><given-names>C</given-names></name>. <article-title>IL-22 Is Mainly Produced by IFNγ-Secreting Cells but Is Dispensable for Host Protection against Mycobacterium tuberculosis Infection</article-title>. <source>PLoS One</source>. <year>2013</year>;<volume>8</volume>(<issue>2</issue>):<fpage>37</fpage>–<lpage>40</lpage>.</mixed-citation>
              </ref>
              <ref id="pone.0217091.ref043">
                <label>43</label>
                <mixed-citation publication-type="journal"><name><surname>Tameris</surname><given-names>MD</given-names></name>, <name><surname>Hatherill</surname><given-names>M</given-names></name>, <name><surname>Landry</surname><given-names>BS</given-names></name>, <name><surname>Scriba</surname><given-names>TJ</given-names></name>, <name><surname>Snowden</surname><given-names>MA</given-names></name>, <name><surname>Lockhart</surname><given-names>S</given-names></name>, <etal>et al</etal><article-title>Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial</article-title>. <source>Lancet</source> [Internet]. <year>2013</year>;<volume>381</volume>(<issue>9871</issue>):<fpage>1021</fpage>–<lpage>8</lpage>. Available from: <pub-id pub-id-type="doi">10.1016/S0140-6736(13)60177-4</pub-id>
<?supplied-pmid 23391465?><pub-id pub-id-type="pmid">23391465</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0217091.ref044">
                <label>44</label>
                <mixed-citation publication-type="journal"><name><surname>Tameris</surname><given-names>M</given-names></name>, <name><surname>Hokey</surname><given-names>DA</given-names></name>, <name><surname>Nduba</surname><given-names>V</given-names></name>, <name><surname>Sacarlal</surname><given-names>J</given-names></name>, <name><surname>Laher</surname><given-names>F</given-names></name>, <name><surname>Kiringa</surname><given-names>G</given-names></name>, <etal>et al</etal><article-title>A double-blind, randomised, placebo-controlled, dose-finding trial of the novel tuberculosis vaccine AERAS-402, an adenovirus-vectored fusion protein, in healthy, BCG-vaccinated infants</article-title>. <source>Vaccine</source> [Internet]. <year>2015</year>;<volume>33</volume>(<issue>25</issue>):<fpage>2944</fpage>–<lpage>54</lpage>. Available from: <pub-id pub-id-type="doi">10.1016/j.vaccine.2015.03.070</pub-id>
<?supplied-pmid 25936724?><pub-id pub-id-type="pmid">25936724</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0217091.ref045">
                <label>45</label>
                <mixed-citation publication-type="journal"><name><surname>Tameris</surname><given-names>M</given-names></name>, <name><surname>Geldenhuys</surname><given-names>H</given-names></name>, <name><surname>Luabeya</surname><given-names>AK</given-names></name>, <name><surname>Smit</surname><given-names>E</given-names></name>, <name><surname>Hughes</surname><given-names>JE</given-names></name>, <name><surname>Vermaak</surname><given-names>S</given-names></name>, <etal>et al</etal><article-title>The candidate TB vaccine, MVA85A, induces highly durable Th1 responses</article-title>. <source>PLoS One</source>. <year>2014</year>;<volume>9</volume>(<issue>2</issue>).</mixed-citation>
              </ref>
              <ref id="pone.0217091.ref046">
                <label>46</label>
                <mixed-citation publication-type="journal"><name><surname>Graves</surname><given-names>AJ</given-names></name>, <name><surname>Padilla</surname><given-names>MG</given-names></name>, <name><surname>Hokey</surname><given-names>DA</given-names></name>. <article-title>OMIP-022: Comprehensive Assessment of Antigen-Specific Human T Cell Functionality and Memory</article-title>. <source>Cytom Part A</source>. <year>2014</year>;<volume>85</volume>(<issue>7</issue>):<fpage>576</fpage>–<lpage>9</lpage>.</mixed-citation>
              </ref>
              <ref id="pone.0217091.ref047">
                <label>47</label>
                <mixed-citation publication-type="journal"><name><surname>Frentsch</surname><given-names>M</given-names></name>, <name><surname>Arbach</surname><given-names>O</given-names></name>, <name><surname>Kirchhoff</surname><given-names>D</given-names></name>, <name><surname>Moewes</surname><given-names>B</given-names></name>, <name><surname>Worm</surname><given-names>M</given-names></name>, <name><surname>Rothe</surname><given-names>M</given-names></name>, <etal>et al</etal><article-title>Direct access to CD4+ T cells specific for defined antigens according to CD154 expression</article-title>. <source>Nat Med</source>. <year>2005</year>;<volume>11</volume>(<issue>10</issue>):<fpage>1118</fpage>–<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1038/nm1292</pub-id>
<?supplied-pmid 16186818?><pub-id pub-id-type="pmid">16186818</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0217091.ref048">
                <label>48</label>
                <mixed-citation publication-type="journal"><name><surname>Lahey</surname><given-names>T</given-names></name>, <name><surname>Mitchell</surname><given-names>BK</given-names></name>, <name><surname>Arbeit</surname><given-names>RD</given-names></name>, <name><surname>Sheth</surname><given-names>S</given-names></name>, <name><surname>Matee</surname><given-names>M</given-names></name>, <name><surname>Robert</surname><given-names>C</given-names></name>, <etal>et al</etal><article-title>Polyantigenic Interferon-γ Responses Are Associated with Protection from TB among HIV-Infected Adults with Childhood BCG Immunization</article-title>. <source>PLoS One</source>. <year>2011</year>;<volume>6</volume>(<issue>7</issue>):<fpage>2</fpage>–<lpage>7</lpage>.</mixed-citation>
              </ref>
              <ref id="pone.0217091.ref049">
                <label>49</label>
                <mixed-citation publication-type="journal"><name><surname>Fine</surname><given-names>PEM</given-names></name>, <name><surname>Ponnighaus</surname><given-names>JM</given-names></name>. <article-title>Leprosy in Malawi Prevention Trial: Background, design and prospects of the Karonga leprosy vaccine trial in northern Malawi</article-title>. <source>Trans R Soc Trop Med Hyg</source>. <year>1988</year>;<volume>82</volume>(<issue>6</issue>):<fpage>810</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/0035-9203(88)90003-x</pub-id>
<?supplied-pmid 3076995?><pub-id pub-id-type="pmid">3076995</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0217091.ref050">
                <label>50</label>
                <mixed-citation publication-type="journal"><name><surname>Sepulveda</surname><given-names>RL</given-names></name>. <article-title>Case-control study of the efficacy of BCG immunization against pulmonary tuberculosis in young adults in Santiago, Chile</article-title>. <source>Tuber Lung Dis</source>. <year>1992</year>;<fpage>372</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/0962-8479(92)90043-J</pub-id>
<?supplied-pmid 1292719?><pub-id pub-id-type="pmid">1292719</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0217091.ref051">
                <label>51</label>
                <mixed-citation publication-type="journal"><name><surname>Nunes-Alves</surname><given-names>C</given-names></name>, <name><surname>Booty</surname><given-names>MG</given-names></name>, <name><surname>Carpenter</surname><given-names>SM</given-names></name>, <name><surname>Jayaraman</surname><given-names>P</given-names></name>, <name><surname>Rothchild</surname><given-names>AC</given-names></name>, <name><surname>Behar</surname><given-names>SM</given-names></name>. <article-title>In search of a new paradigm for protective immunity to TB</article-title>. <source>Nat Rev Microbiol</source> [Internet]. <year>2014</year>;<volume>12</volume>(<issue>4</issue>):<fpage>289</fpage>–<lpage>99</lpage>. Available from: <pub-id pub-id-type="doi">10.1038/nrmicro3230</pub-id>
<?supplied-pmid 24590243?><pub-id pub-id-type="pmid">24590243</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
